Cryoport Reports Q3 2025 Earnings with Revenue Growth and Improved EBITDA
Cryoport (CYRX) reported Q3 2025 earnings with revenue growth across multiple segments, including Commercial Cell and Gene Therapy and Life Sciences Services. The company also noted a reduction in adjusted EBITDA loss and raised its full-year 2025 revenue guidance. The results reflect strong demand for cryogenic systems and integrated storage services.
Tickers: $CYRX
Topics: biostorage cell and gene therapy earnings EBITDA financial performance guidance life sciences services revenue growth